Epidermal growth factor receptor (EGFR) is overexpressed in up to 60% of human pancreatic cancers [5], therefore blocking the EGFR pathway could be a promising strategy for treating pancreatic cancers. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.